Initiation of rheumatoid arthritis treatments and the risk of serious infections.

OBJECTIVE In clinical trials of RA patients on traditional DMARDs, the addition of TNF-alpha antagonists increased infections compared with addition of placebo. Our objective was to compare serious infections following initiation of different RA regimens. Prior comparative studies of DMARD initiation have yielded conflicting results. METHODS We estimated hospitalization rates for infections following initiation of TNF-alpha antagonists, other DMARDs and oral glucocorticoids in Tennessee Medicaid-enrolled RA patients (1995-2005). Exposure time was measured using pharmacy information and infections were identified using validated definitions. Initiation of RA regimens was compared using Cox regression models with MTX as the reference. Sensitivity analyses excluded glucocorticoid users, applied a first exposure carried forward approach, restricted observations to 2002-05 and first episodes of use and explored effects of unmeasured confounders. RESULTS We identified 28 906 new episodes of medication use, including TNF-alpha antagonists (8%), MTX alone (15%) and glucocorticoids alone (57%). Compared with MTX initiation, TNF-alpha antagonist initiation did not significantly increase the risk of hospitalizations for pneumonia [adjusted hazard ratio (aHR) 1.61; 95% CI 0.85, 3.03] or any infection (aHR 1.31; 95% CI 0.78, 2.19). Initiation of LEF, SSZ or HCQ did not increase serious infections, compared with MTX. Both initiation and concurrent glucocorticoid use were associated with a dose-dependent increase in serious infections. Sensitivity analyses showed consistent results. CONCLUSIONS Compared with initiation of MTX alone, initiation of TNF-alpha antagonists was not associated with a large increase in the risk of serious infections. Glucocorticoid use was associated with a dose-dependent increase in the risk of these infections.

[1]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[2]  M. Boers,et al.  Keeping up appearances , 2002, Annals of the rheumatic diseases.

[3]  Frederick Wolfe,et al.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.

[4]  D. Furst.  The risk of infections with biologic therapies for rheumatoid arthritis. , 2010, Seminars in arthritis and rheumatism.

[5]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[6]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[7]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[8]  S. Schneeweiss,et al.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. , 2007, Journal of clinical epidemiology.

[9]  W A Ray,et al.  Use of Medicaid data for pharmacoepidemiology. , 1989, American journal of epidemiology.

[10]  Sebastian Schneeweiss,et al.  Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis , 2007 .

[11]  J. Allison,et al.  Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.

[12]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[13]  B. Psaty,et al.  Assessment and Control for Confounding by Indication in Observational Studies , 1999, Journal of the American Geriatrics Society.

[14]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[15]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[16]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.

[17]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[18]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[19]  J. Avorn,et al.  Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[20]  K. Lohr,et al.  Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis , 2008, Annals of Internal Medicine.

[21]  S. Schneeweiss,et al.  Performance of a rheumatoid arthritis records-based index of severity. , 2005, The Journal of rheumatology.

[22]  P. Gideon,et al.  Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis , 2008, Pharmacoepidemiology and drug safety.

[23]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[24]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[25]  P. Arbogast,et al.  Assessment of Adherence to and Persistence on Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis , 2007, Medical care.

[26]  A. Silman,et al.  The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64 Suppl 4:iv42–3 , 2022 .

[27]  S. Schneeweiss,et al.  The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. , 2008, Arthritis and rheumatism.

[28]  G. Cooper,et al.  The Utility of Administrative Data for Measuring Adherence to Cancer Surveillance Care Guidelines , 2007, Medical care.

[29]  A. Silman,et al.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[30]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[31]  L. J. Wei,et al.  The Robust Inference for the Cox Proportional Hazards Model , 1989 .

[32]  R. Caporali,et al.  DMARDS and infections in rheumatoid arthritis. , 2008, Autoimmunity reviews.

[33]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[34]  C. Stein,et al.  Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. , 2008, Rheumatology.

[35]  Daniel Solomon,et al.  Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture , 2008, Annals of Internal Medicine.

[36]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[37]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[38]  Jeffrey N Katz,et al.  Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[39]  G. Newsome.  Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.

[40]  M. Boers,et al.  Glucocorticoids in the treatment of early and late RA , 2003, Annals of the rheumatic diseases.